The multinational, multi-institutional clinical Phase II trial of
gefitinib monotherapy, IDEAL (
IRESSA Dose Evaluation in Advanced
Lung Cancer) 1, included Japanese and non-Japanese patients with advanced
non-small-cell lung cancer (NSCLC) pretreated with one or more
chemotherapy regimens, at least one including
platinum. To investigate whether survival is affected by gender or histological type of
cancer, a retrospective, exploratory subset analysis was conducted including only Japanese patients from
IDEAL 1 (n = 102 in total, 51 each in 250 and 500 mg/day groups). The median survival time of the 102 patients was 12.0 months and the one year survival rate was 50%. The median survival time was 13.8 months for the 250 mg/day group and 11.2 months for the 500 mg/day group and the one-year survival rate was 57% and 45% respectively. Survival was longer in patients with
adenocarcinoma than those with other histological types of
cancer, and was longer in those with symptom improvement than without. The median survival time in females was longer than that in males. The results suggest that
gefitinib could be superior to classical
anticancer agents with regard to not only the response rate but also survival time in patients with NSCLC, particularly
adenocarcinoma, previously treated with
chemotherapy. Further studies are needed to identify factors affecting survival.